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Introduction
Spontaneous abortions (SA) are one of the most frequent 
pregnancy disorders and are defined as the loss of fetal prod-
uct before 22 weeks of gestation [2]. SA is observed in ap-
proximately 15-20% of total pregnancies [3], although this 
proportion could even be higher. Roughly 1 in 5 pregnan-
cies would, thus, end in spontaneous abortion, the major-
ity until the gestational age of 12-14 weeks, and 1-2% would 
account for recurrent spontaneous abortions [2]. Recurrent 
miscarriage (RM) is defined as the occurrence of three or 
more consecutive losses of pregnancy [5]. However, many 
clinicians define RM as two or more losses and this increases 
the percentage of RM from 1% to 5% of all couples trying 
to conceive. RM is a very frustrating condition for both the 
couple and the clinician, because it is difficult to find a dis-
tinct reason for the repeated failure to sustain a pregnancy 
and eventually have a successful pregnancy outcome. The 
causes involved in RM are numerous: anatomical, endo-
crine, immunological, infectious, environmental, and ge-
netic or combinations of these [3]. Not infrequently, despite 
all medical advances, these causes cannot be identified with 
certainty, and the abortion declared idiopathic remains the 
final diagnosis in approximately 50% of cases [2].
During the past decade, the list of candidate causes of re-
current pregnancy loss (RPL) has grown rapidly. During the 
early 1990s, an elevated plasma homocysteine concentration, 
which has been described as a risk factor for arteriosclerosis, 
venous thrombosis, neural tube defects, placental abruption 
or infarction and preeclampsia, was also suggested to be as-
sociated with RPL [8,10].
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Abstract
Background: It is known that etiological structure of recurrent miscarriage has genetic, anatomical, infectious and immunological factors; however, 
the cause of recurrent miscarriage in 50-60% of cases is not completely clear. Homocysteine is a sulfur-containing intermediate product in the normal 
metabolism of methionine. Development mechanisms of vascular complications of hyperhomocysteinemia are currently being intensively studied. 
Hyperhomocysteinemia affects a number of mechanisms involved in thrombogenesis including coagulation cascade, vessel-thrombocytic section, 
oxidation-reduction reactions, endothelium, and vascular smooth muscle cells and is associated with an increased risk of adverse outcomes in pregnancy. 
Materials and methods: The study included 50 women who had experienced the loss of at least two consecutive pregnancies. The level of the total serum 
homocysteine was measured via the chemiluminescent method.
Results: We found that plasma homocysteine concentration < 10 μmol/l was found in 16 patients (32,0%, 95% CI 19,07 – 44,93), 9 patients (18.0%, 95% 
CI 7,36 – 28,64) had a fasting plasma homocysteine between 10 μmol/l to 12 μmol/l and 25 patients (50.0%, 95%CI 36,15 – 63,85) had significantly high 
total serum homocysteine values. Among them, 23 patients (46.0%, 95%CI 32,19 – 59,81) had the concentration between 12 – 30 μmol/l and 2 patients 
(4,0%, 95%CI -1,43 – 9,43) had the concentration > 30μmol/l. The complex of B vitamin supplementation was recommended at least 2 to 3 months 
before conception. In the current study, 40 women (80.0%, 95% CI 68,92 – 91,08) have become pregnant, passed the critical periods for pregnancy loss 
and continued the folate intake during the pregnancy. 
Conclusions: The prevalence of hyperhomocysteinemia was more in unexplained primary early recurrent miscarriages. The complex of B vitamin 
supplementation was recommended at least 2 to 3 months before conception and 40 women (80.0%, 95% CI 68,92 – 91,08) became pregnant, passed the 
critical periods for pregnancy loss and continued the folate intake during the pregnancy.
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Several reports have clearly shown an association of el-
evated homocysteine concentrations and obstetric diseases 
that are connected with vascular disorders of pregnancy or 
of the utero-placental unit [3].
Nelen et al. [8] studied women with repeated miscar-
riages and found a direct relationship between high levels 
of homocysteine and defective chorionic villous vasculariza-
tion: early miscarriages might be explained by the damage 
that excess homocysteine may cause on chorionic and decid-
ual vessels leading to defective implantation of the embryo. 
Placental development in early pregnancy may be negatively 
influenced by increased maternal homocysteine concentra-
tions [1]. Experimental studies revealed that moderately el-
evated homocysteine concentrations may induce cytotoxic 
and oxidative stress, leading to endothelial cell impairment 
[1, 6, 13, 16]. Additionally, exposure of trophoblast cells to 
homocysteine may increase cellular apoptosis and lead to 
inhibition of trophoblastic function [1,3]. Recently, Di Sim-
one et al. [3] provided the first demonstration that human 
placenta is a target for homocysteine and suggested that tro-
phoblast death might represent one mechanism by which 
homocysteine causes pregnancy complications related to 
placental diseases.
The aim of this study was to evaluate the level of plasma 
homocysteine concentration in a group of women with re-
current pregnancy loss and to investigate the association be-
tween them in order to look for hypothetical possibilities of 
therapeutic interventions.
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Material and methods
The study included 50 women of fertile age with at least 
two consecutive miscarriages in the first and second trimes-
ter of gestation. All the enrolled cases have no identified 
causes of abortions. The patients were recruited at the De-
partment of Obstetrics and Gynecology No 2, Nicolae Tes-
temitsanu State University of Medicine and Pharmacy and 
at the medical center “Repromed”of Chisinau city, the Re-
public of Moldova from April to September in 2014 to 2016. 
The cases were identified and selected when they visited the 
above-mentioned hospitals for investigation of two or more 
consecutive unexplained terminations of pregnancy. Wom-
en with clinical diagnosis of metabolic deseases, renal insuf-
ficiency and a woman who took vitamin supplements were 
excluded from this study. Socioeconomic data (schooling 
and occupation) and obstetrics data were assessed by ques-
tionnaire. Written informed consent was obtained from all 
women before participation. The study was approved by the 
Ethics Committee of the Nicolae Testemitsanu State Univer-
sity of Medicine and Pharmacy, Chisinau, the Republic of 
Moldova.
The measurements of plasma homocysteine concentra-
tion were performed using chemiluminescence method. 
Blood samples were drawn from women using sterile tubes 
with anticoagulant (EDTA) and the plasma for the analysis 
of total homocysteine concentration was centrifuged imme-
diately.
The lowering homocysteine level therapy included vita-
min supplementation (folic acid, vitamin B12 and vitamin 
B6) and was also recommended to eat a diet rich in vitamins, 
as a part of preconception care.
The Microsoft Excel application (Microsoft Office 2010) 
and online OpenEpi application, version 2.3.1 [9] were used 
for the statistical analysis. Parametric variables were com-
pared by Student’s t-test and the 95% confidence interval 
(CI) was calculated.
Results and discussion
The median age of the 50 women in the study group 
was 29,52±5.89 years, ranging from 20 to 42 years old. The 
documentation of patients’ places of residence identified 
that 27 respondents (54,0%, 95% CI 40,19 – 67,81) were 
from urban area and 23 respondents (46,0%, 95% CI 32,19 
– 59,81) were from rural area. The study has included 4 stu-
dents (8,0%, 95% CI 0,49 – 15,51), 28 respondents (56,0%, 
95% CI 42,25 – 69,75) were engaged in an intellectual type 
of work, 13 respondents (26,0%, 95% CI 13,49 – 38,51) were 
workers and 5 respondents (10,0%, 95% CI 1,69 – 18,31) 
performed housework.
The gestational age, when the abortions occurred, was di-
vided into the first and the second trimester of gestation and 
mixed when there were intersessions between them. Our 
data show that in 44 women (88,0%, 95% CI 79,0 – 97,0), the 
abortion occurred in the first trimester, in 1 woman (2,0%, 
95% CI -1,43 – 9,43) 22 (25%) the abortion occurred in the 
second trimester and 5women (10,0%, 95% CI 1,69 – 18,31) 
were included in the mixed abortion group, because they 
presented these events in the first and second trimester dur-
ing their pregnancies (fig. 1). We can conclude that 49 pa-
tients (98,0%, 95% CI 94,12 – 101,88) had early RPL and 6 
patents (12,0%, 95% CI 3,0 – 21,0) had late RPL.
Fig. 1.  The gestational – age distribution of spontaneous 
abortion in the study (%).
The median abortion number in the study group was 
2,32±0,62, ranging from 2 to 5 abortions, in which 37 
women (74,0%, 95% CI 61,85 – 86,15) had two spontane-
ous abortions; 11 (22,0%, 95% CI 10,52 – 33,48) of them had 
three spontaneous abortions, 1 (2,0%, 95% CI -1,43 – 9,43) 
of them had four spontaneous abortions and, also, 1 (2,0%, 
95% CI -1,43 – 9,43) of them had five spontaneous abortions 
(fig. 2).
Fig. 2.  The frequency of spontaneous  
abortions in the study (%).
Also, 33 patients (66,0%, 95% CI 52,87 – 79,13) were 
classified as suffering from primary RPL when they had 
never had a live birth before and 17 patients (34,0%, 95% CI 
20,87-47,13) suffering from secondary RPL when they had 
recurrent losses following a successful pregnancy (fig. 3).
The median fasting total plasma homocysteine concen-
tration was 13,36±1,0 μmol/l, ranging from 2,19 mmol/l to 
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34,7 mmol/l. 
According to the D.A.CH. – Liga Homocysteine (Ger-
man, Austrian, and Swiss Homocysteine Society) fasting 
total serum homocysteine (< 10 μmol/l) is considered safe 
and should be the target level during homocysteine-low-
ering treatment [13]. Vollset et al. [16] reported that the 
women with the highest level of homocysteine (greater than 
10 μmol/l) have an adjusted risk for preeclampsia. Ronnen-
berg et al. [12] demonstrated that the risk of preterm birth 
was nearly 4-fold higher among women with preconception 
homocysteine concentrations ≥ 12.4 μmol/l compared to 
women who had lower homocysteine concentrations. Urban 
et al. [15] mentioned that the mean serum homocysteine 
concentration was 11,50 μmol/l in the group of patients with 
intrauterine fetal growth restriction compared to the group 
of normal pregnacies who had lower homocysteine concen-
trations – 9,58 μmol/l.
Taking in consideration the information mentioned 
above, for these analyses, we defined elevated homocysteine 
as a plasma concentration of homocysteine > 10 μmol/l.
Fig. 4.  Distribution of the plasma homocysteine  
level in the study group (%).
The results of our investigations showed that plasma 
homocysteine concentration < 10 μmol/l was found in 16 
patients (32,0%, 95% CI 19,07 – 44,93), 9 patients (18,0%, 
95% CI 7,36 – 28,64) had a fasting plasma homocysteine be-
tween 10 μmol/l to 12 μmol/l and 25 patients (50,0%, 95%CI 
36,15 – 63,85) had significantly high total serum homocys-
teine values (fig. 4). Among them, 23 patients (46,0%, 95%CI 
32,19 – 59,81) had the concentration between 12 – 30 μmol/l 
and 2 patients (4,0%, 95%CI -1,43 – 9,43) had the concentra-
tion > 30μmol/l.
Ueland et al. suggested that the correlation between pre-
conceptional total serum homocysteine and total serum 
homocysteine during pregnancy points to the possibility 
that preconceptional total serum homocysteine may predict 
homocysteine-associated pregnancy complications [14]. As 
a result, we defined that 34 patients (68,0%, 95% CI 55,07 
– 74,93) had elevated serum homocysteine (higher than 10 
μmol/l, according to our initial consideration). 
In this context, it was evaluated total plasma homocyste-
ine concentration in relation to the type of recurrent miscar-
riage in women with unexplained pregnancy loss (tab. 1).
Table 1
Total plasma homocysteine concentration in relation to 
the type of recurrent miscarriage in the study group
Total plasma homo-
cysteine concentra-
tion (μmol/l)
Primary RPL Secondary RPL t p
14,48±1,49 11,55±0,94 1.6631 >0.05
The results of our investigations showed that homocys-
teine levels in the blood serum of patients suffering from 
primary RPL was higher (14,48±1,49 μmol/l) compared to 
patients suffering from secondary RPL (11,55±0,94 μmol/l) 
(p >0.05).
We found that the total serum homocysteine concen-
tration in the study group was higher (13,50±1,01 μmol/l) 
in the patients with a history of early RPL (tab. 2) than in 
the patients with a history of late RPL (9,98±1,69 μmol/l) 
(p >0.05).
Table 2
Total plasma homocysteine concentration according to 
the stage of pregnancy loss in the study group
Total plasma homo-
cysteine concentra-
tion (μmol/l)
Early RPL Late RPL t p
13,50±1,01 9,98±1,69 1.7879 >0.05
Patients who had ≥3 abortions showed a significantly 
higher total serum homocysteine concentration (15,76± 
1,82 μmol/l) when compared to patients who had 2 sponta-
neous abortions (12,51±1,18 μmol/l) (p >0.05) (tab. 3).
Table 3
Total plasma homocysteine concentration according to 
the number of abortions in the study group
Total plasma 
homocysteine 
concentration 
(μmol/l)
2 spontaneous 
abortions
≥3 spontaneous 
abortions
t p
12,51±1,18 15,76±1,82 1.49783 >0.05
Fig. 3.  Type of pregnancy loss in recurrent  
miscarriage in the study (%).
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Hyperhomocyteinemia can cause obstetrical diseases 
that are connected with vascular disorders of pregnancy or 
the uteroplacental unit [8]. Gris et al. [5] reported an asso-
ciation between increased levels of homocysteine and a first 
early pregnancy loss. Kumar et al. [6] considered elevated 
homocysteine levels to be a risk factor for recurrent preg-
nancy loss. 
In the current study, we found that the incidence of 
hyperhomocysteinemia was higher in women with unex-
plained primary early recurrent miscarriages.
Nutritional factors, particularly consumption and seric 
concentration of folate, vitamin B12 and B6, seem to be the 
major parameters in homocysteine metabolization. Defi-
ciencies, isolated or combined, of vitamins involved in the 
various pathways of homocysteine metabolism would be im-
portant markers for hyperhomocysteine [7].
An adequate intake of at least 400 μg of folate per day is 
difficult to maintain even with a balanced diet, and high-risk 
groups often find it impossible to meet these folate require-
ments. The bioavailability of dietary folates is 55 %. As the 
recommendation to eat a healthy diet has little or limited 
impact on elevated homocysteine levels, (folate)-fortified 
foods and/or vitamin supplements are rational and therefore 
recommended. [13]
Maternal hyperhomocysteinemia is related to birth de-
fects, including neural tube defects (NTDs), orofacial clefts, 
clubfoot, and Down syndrome. Folic acid supplements in the 
periconceptual period and the first few weeks of pregnancy 
reduce the risk of NTDs [10,11]. For this reason, all women 
of childbearing age should have a folate intake of at least 400 
μg/day [10,17].
Vitamin supplementation continues to be a recommend-
able option for prophylaxis of hyperhomocysteinemia. Dos-
ages for prophylaxis are given in Figure 5 (low-dose supple-
mentation: folic acid – 0.2 to 0.8 mg/day; vitamin B12 – 3 to 
100 μg/day; vitamin B6 – 2 to 25 mg/day). If this supplemen-
tation regimen lowers plasma homocysteine to <10 μmol/l 
within 4 weeks, repeated measurements of plasma homocys-
teine should be obtained first every 6 months and later on 
once a year. If response (plasma homocysteine reduction) is 
still inadequate, the dosage of folic acid should be increased 
to, say, 1 to 5 mg of folic acid per day (while supplementa-
tion with vitamin B12 and vitamin B6 can be continued un-
changed for some time). Repeated determinations of plasma 
homocysteine should be performed at 4-week intervals. [13]
There are biologically plausible reasons that increased 
total serum homocysteine may be related to adverse preg-
nancy outcomes. Increased total serum homocysteine may 
directly or indirectly cause endothelial dysfunction, impair 
neurolation, reduce microfilament synthesis, inhibit DNA 
methylation and alter gene expression, and reduce S-adeno-
sylmethionine-dependent methylation reactions [10].
Regarding plasma levels of homocysteine, subjects were 
divided into two groups: group I – women with plasma ho-
mocysteine concentration < 10 μmol/l (n = 16) and group 
II – women with plasma homocysteine concentration > 10 
μmol/l (n = 32).
In our study, we recommended a complex of B vitamin 
supplementation (folic acid – 0,4 mg/day; vitamin B12 – 3 to 
100 μg/day; vitamin B6 – 2 to 25 mg/day) for women with 
plasma homocysteine concentration < 10 μmol/l and a com-
plex of B vitamin supplementation (folic acid:1 – 5 mg; vi-
tamina B12: 100 – 600 μg; vitamina B6: 6 – 25 mg) for women 
with plasma homocysteine concentration > 10 μmol/l. Also, 
everybody was recommended to eat a diet rich in vitamins.
The complex of B vitamin supplementation was recom-
mended at least 2 to 3 months before conception. As a re-
sult, in the first group only 10 women (62,5%, 95% CI 38,78 
– 86,22) from 16 women became pregnant. In the second 
group, 32 women (94,11%, 95% CI 48,01 – 140,21) became 
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Fig. 5.  Decision tree for diagnosis and prophylaxis/treatment of hyperhomocysteinemia [13].
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pregnant, of which 2 women had a miscarriage in the first 
trimester of pregnancy. All the pregnant patients passed the 
critical periods for pregnancy loss and continued the folate 
intake during the pregnancy. However, because of the small 
number of selected patients, our data should be confirmed 
by further studies based on larger population.
Conclusions
1. Our study provides data concerning the involvement 
of homocysteine in women with RPL without other causes 
of recurrent abortion. We found that the incidence of hyper-
homocysteinemia was higher in women with unexplained 
primary early recurrent miscarriages.
2. The complex of B vitamin supplementation and, also, a 
diet rich in vitamins was recommended at least 2 to 3 months 
before conception.
3. In the current study, 40 women (80,0%, 95% CI 68,92 
– 91,08) became pregnant, passed the critical periods for 
pregnancy loss and continued the folate intake during the 
pregnancy.
4. Because of the small number of selected patients, our 
data should be confirmed by further studies based on larger 
population.
References
1. Bergen N. et al. Homocysteine and folate concentrations in early preg-
nancy and the risk of adverse pregnancy outcomes: the Generation R 
Study. BJOG: an international journal of obstetrics and gynaecology, 
2012, 119 (6), 739 – 751.
2. Cao Y. et al. The association of idiopathic recurrent early pregnancy loss 
with polymorphisms in folic acid metabolism-related genes. Genes & 
Nutrition, 2014, 9: 402, 1-8.
3. Di Simone. et al. Effect of folic acid on homocysteine-induced trophoblast 
apoptosis. In: Molecular Human Reproduction, 2004, 10 (9), 665 – 669.
4. Furness D. et al. Folate,Vitamin B12,Vitamin B6 and homocysteine: 
impact on pregnancy outcome. Maternal and Child Nutrition, 2011, 1-12.
5. Gris J. et al. Antiphospholipid/antiprotein antibodies, hemostasis-
related autoantibodies, and plasma homocysteine as risk factors for a 
first early pregnancy loss: a matched case-control study. Blood, 2003, 
10, 3502 – 3513.
6. Kumar K. et al. Plasma homocysteine levels correlated to interactions 
between folate status and methylene tetrahydrofolate reductase gene 
mutation in women with unexplained recurrent pregnancy loss. Journal 
of obstetrics and gynaecology: the journal of the Institute of Obstetrics 
and Gynaecology, 2003, 23, 55 – 58.
7. Luciene de Souza Venancio, Roberto Carlos Burini, Winston Bonetti 
Yoshida. Dietary treatment of hyperhomocysteinemia in peripheral 
arterial disease. Jornal Vascular Brasileiro, 2010, 9 (1), 28-41.
8. Nelen W. et al. Homocysteine and folate levels as risk factors for 
recurrent early pregnancy loss. Obstetrics and Gynecology, 2000, 95, 
519 – 524.
9. OpenEpi 2.3.1 – Open Source Epidemiologic Statistics for Public 
Health, http://www.openepi.com (visited 16.11.2016)
10. Refsum H. et al. Facts and Recommendations about Total Homocys-
teine Determinations: An Expert Opinion. Clinical Chemistry, 2004, 
50 (1), 3- 32.
11. Refsum Helga. Folate, vitamin B12 and homocysteine in relation to 
birth defects and pregnancy outcome. British Journal of Nutrition, 
2001, 85, Suppl. 2, S109-S113.
12. Ronnenberg A. et al. Preconception homocysteine and B vitamin status 
and birth outcomes in Chinese women. American Journal of Clinical 
Nutrition, 2002, 76, 1385 – 1391.
13. Stanger O. et al. Clinical use and rational management of homocysteine, 
folic acid, and B vitamins in cardiovascular and thrombotic diseases. 
In: Zeitschrift für Kardiologie, 2004, 93, 439 – 453.
14. Ueland P., Vollset S. Homocysteine and Folate in Pregnancy. Clinical 
Chemistry, 2004, 8, 1293 – 1295.
15. Urban J. et al. Serum homocysteine and nitric oxide levels in pregnancy 
complicated with intrauterine fetal growth restriction. Archives of 
Perinatal Medicine, 2007, 13 (3), 27 – 29.
16. Vollset S. et al. Plasma total homocysteine, pregnancy complications, 
and adverse pregnancy outcomes: the Hordaland Homocysteine Study. 
American Journal of Clinical Nutrition, 2000, 71, 962 – 968.
17. WHO. WHO recommendations on antenatal care for a positive preg-
nancy experience. Geneva, World Health Organization, 2016. http://
apps.who.int/iris/bitstream/10665/250796/1/9789241549912-eng.
pdf?ua=1 (visited 20.12.2016).
19
